Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers.

Abstract

The new anthracycline analogue, 4'-iodo-4'-deoxydoxorubicin (I-DOX), was administered at 70 mg/m2 as first chemotherapy in 61 patients with advanced NSCL (19), colon (20) and breast cancers (22). Treatment was repeated every 3 weeks; the dose was decreased to 60 mg/m2 (19% of the cycles) or increased to 80 mg/m2 (17% of the cycles) according to the granulocyte count nadir. Partial responses were observed in 6% of the patients with NSCL, in 5.5% of those with colon and in 10% of those with breast cancers. The main toxicity was a selective granulocytopenia characterized by a duration of about 1 week, and a high inter-patient variability. Non-haematological toxicities were mild. The negative results obtained in breast cancer might be related to the dose administered. Further studies in this tumour type should be performed with a more aggressive schedule.

• Authors: C Sessa, F Calabresi, F Cavalli, T Cerny, P Liati, T Skovsgaard, R Sorio, S B Kaye
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) 1991 Nov-Dec Vol. 2 Issue 10 Pg. 727-31 ISSN: 0923-7534 [Print] England
• PMID: 1666296 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• 4'-deoxy-4'-iododoxorubicin
• Doxorubicin

Topics

• Adult
• Aged
• Agranulocytosis (chemically induced)
• Breast Neoplasms (drug therapy)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Colonic Neoplasms (drug therapy)
• Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged